Compared with those of the AD model group, the protein expression levels of GFAP, AQP4, IL-1β, and TNF-α were significantly downregulated in the β-asarone treatment group (55.6, 166.7 μg/mL), and these results were similar to those of the mRNA expression analysis. This evidence concerns the gene IL1B and Alzheimer disease.